MedPath

Descriptive Analysis of Real-world Data Collected with ME&MGopen

Completed
Conditions
Myasthenia Gravis
Interventions
Device: ME&MGopen smartphone application
Registration Number
NCT05566964
Lead Sponsor
Ad scientiam
Brief Summary

The ME\&MGopen smartphone application is an investigational software for research purposes only, developed by Ad Scientiam. It features digital tests to assess the respiratory capacity ("My Breathing" Test), dysarthria ("My Voice" Test), ptosis ("My eyelids" test), as well as upper and lower limb muscle function ("My arms" Test and "My legs" Test). The mobile app also includes e-questionnaires related to activities of daily living, pain, insomnia, quality of life and depression. The objectives of the study are to collect data on patients' symptoms with the application in a real life setting, to assess adherence to the use of the tool, user experience and satisfaction with the application, and safety of use.

Detailed Description

The ME\&MGopen smartphone application is an investigational software for research purposes only, developed by Ad Scientiam. It features digital tests to assess the respiratory capacity ("My Breathing" Test), dysarthria ("My Voice" Test), ptosis ("My eyelids" test), as well as upper and lower limb muscle function ("My arms" Test and "My legs" Test). The mobile app also includes e-questionnaires related to activities of daily living, pain, insomnia, quality of life and depression.

The objectives of the study are to collect data on patients' symptoms with the application in a real life setting, to assess adherence to the use of the tool, user experience and satisfaction with the application, and safety of use.

Analyses will also be performed to identify factors that may influence these parameters and provide levers for understanding and improvement. The existence of a possible learning effect on active testing will also be explored as a data point of interest.

The results will allow researchers to extend their knowledge of gMG from real-life data and of the use of digital tools in a gMG patient population

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
236
Inclusion Criteria
  • Aged 18 + years old
  • Diagnosis of gMG with positive serologic test for anti-AChR autoantibody at screening
  • Who has read the information sheet and signed the informed consent form
  • Owns a personal smartphone which version is above 14 for IOS and 8 for Android included
  • Able to use a smartphone
  • Able to perform the ME&MG tests (based on investigator's judgment)
  • Able to read language in which the mobile application is available (English, Spanish, German) and able to understand pictograms
Exclusion Criteria
  • Participating in another ME&MG trial
  • Aged 17 years or younger
  • A medical, psychological, or behavioral condition which interferes with compliance

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
ME&MGopenME&MGopen smartphone applicationUse of ME\&MGopen mobile app, at home for 12 months
Primary Outcome Measures
NameTimeMethod
To describe real-life lower limb weakness measurementsThrough study completion, an average of 12 months

Number of sit-to-stand actions measured with the ME\&MGopen smartphone application (1 minute sit-to-stand test)

To describe real-life respiratory capacity measurementsThrough study completion, an average of 12 months

Time in seconds measured with the ME\&MGopen smartphone application : saying "aaaaahhh" for as long as possible

To describe pain symptomsThrough study completion, an average of 12 months

Pain Likert scale scores(0-10) higher score meaning a worse outcome

To describe real-life ptosis measurementsThrough study completion, an average of 12 months

Margin-Reflex Distance 1 (MRD1) measured with the ME\&MGopen smartphone application

To describe real-life dysarthria measurementsThrough study completion, an average of 12 months

Time in seconds measured with the ME\&MGopen smartphone application

To describe depression symptomsThrough study completion, an average of 12 months

Patient Health Questionnaire-8 (0-12) higher score meaning a worse outcome

To describe real-life upper limb weakness mesurementsThrough study completion, an average of 12 months

Time in seconds measured with the ME\&MGopen smartphone application (holding the phone in one arm for as long as possible)

To describe activities of daily livingThrough study completion, an average of 12 months

Myasthenia Gravis Activities of Daily Living scores (0-24) higher score meaning a worse outcome

To describe quality of life related to MGThrough study completion, an average of 12 months

Myasthenia Gravis Quality of Life 15-item Scale revised scores (0-30) higher score meaning a worse outcome

To describe quality of lifeThrough study completion, an average of 12 months

36-Item Short Form Survey version 1 (0-100) higher score meaning a better outcome

To describe insomnia symptomsThrough study completion, an average of 12 months

Insomnia Severity Index scores (0-28) higher score meaning a worse outcome, 0-7 = No clinically significant insomnia 8-14 = Subthreshold insomnia 15-21 = Clinical insomnia (moderate severity) 22-28 = Clinical insomnia (severe)

Secondary Outcome Measures
NameTimeMethod
To assess user behaviorthrough study completion, 30 months

Description of user behavior (counts/percentages)

To assess safety of use of the smartphone applicationthrough study completion, 30 months

Descriptive analysis of adverse events (AEs) related and unrelated to the use of the application. Adverse event data will be reported in a table and expressed as number and percentage, differentiating mild, moderate and severe AEs.

To evaluate the effect of different frequencies of assessments of the digitals tests on the onset of learning effectthrough study completion, 30 months

p-value

To identify if depression , activities of daily living and satisfaction could influence the adherence to the smartphone applicationthrough study completion, 30 months

p-value from multiple regression

To assess adherence to the mobile applicationthrough study completion, 30 months

Descriptive analysis of the mobile application's adherence data (number of completed questionnaires, carried tests, number of sessions performed etc.)

To evaluate the ability of the Health Belief Model to predict user behavior towards the smartphone applicationthrough study completion, 30 months

coefficient of correlation between dimensions of the Health Belief Model and device use

To identify if socio-demographic data, treatment status, severity, satisfaction and user experience could influence the results to the digital tests and questionnairesthrough study completion, 30 months

p-value from multiple regression

To evaluate the reliability of the digital tests performed at home in real-lifeBaseline, month 1, month 2, month 3, Month 4, month 5, month 6, month 7, month 8, month 9, month 10, month 11, month 12

The intraclass correlation coefficient mean k raters (ICCk; k=month) will be used to assess the monthly reliability at home of digital tests from the beginning to the end of participation :

At-home MET At-home MBT At-home MVT At-home MAT At-home MLT

To assess the satisfaction and user experience with the smartphone applicationthrough study completion, 30 months

Descriptive analysis (counts/percentages) of the answers to the user experience and satisfaction questionnaires related to the use of the ME\&MGopen smartphone application

To identify if socio-demographic data or treatment status could influence satisfaction with the smartphone applicationthrough study completion, 30 months

p-value from multiple regression

To analyze correlations between digital tests, e-questionnaires, socio demographic data, treatmentsthrough study completion, 30 months

Matrix correlation to estimate Pearson's correlation coefficient for each pair of relevant variables.

To identify if socio-demographic data, treatment status, severity, satisfaction and user experience could influence the reliability of the digital teststhrough study completion, 30 months

p-value from multiple regression

To explore the existing association between the ME&MG tests scores obtained at home and the results labeled by a trained evaluatorthrough study completion, 30 months

coefficient of correlation

Trial Locations

Locations (3)

The University of North Carolina at Chapel Hill

🇺🇸

Chapel Hill, North Carolina, United States

University Health Network

🇨🇦

Toronto, Ontario, Canada

Lindus Health

🇬🇧

London, Greater london, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath